Target intelligence / Profile preview

Host intestinal mucosa, gut microbiota, and enteric pathogens

Molecular classification
Other, Biological system
01

Overview

The host intestinal mucosa, gut microbiota, and enteric pathogens represent a complex tripartite biological system rather than a single molecular target. The intestinal mucosa serves as a critical physical and immunological barrier, employing mucus layers and tight junctions to maintain separation between the host and the luminal environment (Source: National Center for Biotechnology Information (NCBI), "The Intestinal Barrier: A Fundamental Role in Health and Disease", 2021). The gut microbiota consists of trillions of commensal microorganisms that provide colonization resistance by competing with pathogens for niches and producing antimicrobial metabolites like short-chain fatty acids (Source: Nature Reviews Microbiology, "Mechanisms of colonization resistance", 2018). Enteric pathogens are specialized microorganisms that attempt to bypass these defenses to cause disease, often by inducing inflammation or damaging the epithelial lining (Source: PubMed, "Pathogen-microbiota-host interactions in the gut", 2020). Therapeutic approaches targeting this axis, such as probiotics or fecal microbiota transplants, focus on restoring ecological balance and barrier function. Given its multi-component nature involving various cell types and species, this entity is categorized as a biological interface or ecosystem.

Other names
Gut-microbiota-host axisIntestinal mucosal interfaceHost-microbe-pathogen tripartite interactionGastrointestinal ecosystem
02

Mechanism of action

Modulation of microbial community composition, enhancement of epithelial tight junction integrity, and competitive exclusion of pathogenic attachment.

03

Biological functions

Immune responseBarrier functionNutrient metabolismPathogen exclusionHomeostasis
04

Disease associations

InfectionInflammationInflammatory bowel diseaseIrritable bowel syndromeMetabolic syndrome
05

Safety considerations

DysbiosisAntibiotic resistanceSystemic translocation of bacteriaImmune-mediated inflammation
06

Interacting drugs

Rifaximin

4 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinSecretory IgAMicrobial diversity indexShort-chain fatty acids (SCFAs)

Beyond the preview

Go deeper on Host intestinal mucosa, gut microbiota, and enteric pathogens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host intestinal mucosa, gut microbiota, and enteric pathogens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call